Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

AARTELO BIOSCIENCES, INC.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
A

ARTELO BIOSCIENCES, INC.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
    Sep 23, 2026Artelo Biosciences, Inc. (ARTL) Press Releases
  • Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
    Sep 16, 2026Artelo Biosciences, Inc. (ARTL) Press Releases
  • Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
    Sep 8, 2026Artelo Biosciences, Inc. (ARTL) Press Releases
  • Artelo Biosciences Announces Reverse Stock Split
    Aug 27, 2026Artelo Biosciences, Inc. (ARTL) Press Releases
  • Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
    Aug 20, 2026Artelo Biosciences, Inc. (ARTL) Press Releases
  • Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
    Aug 17, 2026Artelo Biosciences, Inc. (ARTL) Press Releases
  • Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
    Aug 13, 2026Artelo Biosciences, Inc. (ARTL) Press Releases
  • Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma
    Aug 10, 2026Artelo Biosciences, Inc. (ARTL) Press Releases
  • New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
    Jul 22, 2026Artelo Biosciences, Inc. (ARTL) Press Releases
  • Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
    Jul 16, 2026Artelo Biosciences, Inc. (ARTL) Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$4.15Close · Sep 22, 2026